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The fusogenic potential of Class I viral envelope glycoproteins is activated by proteloytic cleavage of the precursor glycoprotein to generate the
mature receptor-binding and transmembrane fusion subunits. Although the coronavirus (CoV) S glycoproteins share membership in this class of
envelope glycoproteins, cleavage to generate the respective S1 and S2 subunits appears absent in a subset of CoV species, including that
responsible for the severe acute respiratory syndrome (SARS). To determine whether proteolytic cleavage of the S glycoprotein might be
important for the newly emerged SARS-CoV, we introduced a furin recognition site at single basic residues within the putative S1–S2 junctional
region. We show that furin cleavage at the modified R667 position generates discrete S1 and S2 subunits and potentiates membrane fusion activity.
This effect on the cell–cell fusion activity by the S glycoprotein is not, however, reflected in the infectivity of pseudotyped lentiviruses bearing the
cleaved glycoprotein. The lack of effect of furin cleavage on virion infectivity mirrors that observed in the normally cleaved S glycoprotein of the
murine coronavirus and highlights an additional level of complexity in coronavirus entry.
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The coronaviruses (CoVs) are a diverse family of enveloped,
positive-sense RNA viruses that are distributed widely among
animal species. The recent emergence of a novel human CoV
responsible for severe acute respiratory syndrome (SARS)
(Drosten et al., 2003; Ksiazek et al., 2003; Kuiken et al., 2003;
Peiris et al., 2003) highlights the public health risks associated
with the continual evolution and zoonotic spread of new CoVs.
The human SARS-CoVof 2002–2003 was likely derived from a
CoV of the civet cat, an animal common to live-animal food
markets in China (Guan et al., 2003). Cross-species transmis-
sion events have also been implicated in the emergence and
establishment of other novel CoVs, such as the transmissible
gastroenteritis virus (TGEV) of pigs (Sanchez et al., 1992) and
the human respiratory CoV OC43 (Vijgen et al., 2005).
The spike (S) glycoprotein of the CoV is an important
determinant of virus host range and pathogenicity (Lai and⁎ Corresponding author. Fax: +1 406 243 6425.
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doi:10.1016/j.virol.2006.02.003Holmes, 2001). This glycoprotein mediates the initial attach-
ment of the virus to host-cell receptors and the subsequent
fusion of the viral and cellular membranes to allow entry of the
virion core. The S glycoproteins within the CoV family differ
among themselves in several features that are reflective of their
serologic and phylogenetic groupings (Gonzalez et al., 2003;
Lai and Holmes, 2001). Of particular interest is the dimorphism
seen with respect to proteolytic maturation of the S glycoprotein
precursor. In the group 2 viruses, such as the prototype murine
hepatitis virus (MHV), and in the avian group 3 viruses, the S
glycoprotein precursor is cleaved, likely by furin-like cellular
proteases (de Haan et al., 2004), to yield the canonical receptor-
binding (S1) and transmembrane fusion (S2) subunits. By
contrast, the S glycoproteins of the group 1 viruses are not
subjected to proteolytic cleavage during biogenesis. Interest-
ingly, the newly emerged SARS-CoV displays characteristics of
both groups: although the SARS-CoV is phylogenetically
related to the group 2 viruses (Gibbs et al., 2004; Snijder et
al., 2003), the S glycoprotein does not show evidence of
proteolytic maturation (Moore et al., 2004; Simmons et al.,
2004; Song et al., 2004; Xiao et al., 2003).
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teins stands in contradistinction to the special role for
proteolytic maturation in the structure and function of other
Class I viral envelope glycoproteins. Cleavage by cellular
proteases is universally required to enable the fusion potential of
the envelope glycoproteins of retroviruses, orthomyxoviruses,
paramyxoviruses, filoviruses and arenaviruses. Upon subse-
quent activation of the matured Class I envelope glycoprotein,
by receptor binding and/or low endosomal pH, these complexes
undergo profound structural reorganization to ultimately form
highly stable trimer-of-hairpins structures that contribute to
fusion of the viral and cellular membranes ((Eckert and Kim,
2001; Hughson, 1997; Skehel and Wiley, 2000; Weissenhorn et
al., 1999) and references therein). Although the SARS-CoV S
glycoprotein is a bona fide member of the Class I fusion
proteins (Bosch et al., 2003; Duquerroy et al., 2005; Follis et al.,
2005; Supekar et al., 2004; Xu et al., 2004), it paradoxically
appears able to initiate membrane fusion without proteolytic
activation and to complete the conformational changes without
proteolytic separation of the S1 and S2 subunits.
The requirement for proteolytic maturation among the
normally cleaved S glycoproteins of the group 2 CoV species
is likewise ambiguous. In the MHV glycoprotein, mutations
that alter the furin protease recognition sequence (R-X-R/K-
R↓; (Molloy et al., 1999; Rockwell et al., 2002) and
references therein) and prevent cleavage generally diminish
cell–cell fusion activity (Bos et al., 1995; de Haan et al.,
2004; Sturman et al., 1985; Taguchi, 1993; Yamada et al.,
1998), yet do not markedly affect viral infectivity or
pathogenesis (Bos et al., 1997; de Haan et al., 2004; Hingley
et al., 2002). By contrast, MHV infectivity can be enhanced
by exogenous treatment with trypsin (Sturman et al., 1985),
raising the possibility that proteases that recognize single
basic residues may be important. Thus, the role of proteolytic
maturation in CoV entry, and the identity of the putative
cellular protease, remains unclear.Fig. 1. Sequence alignment to define the putative S1–S2 junctional region of SARS-C
as accessed in the PredictProtein suite (http://cubic.bioc.columbia.edu/predictprotein)
following CoV S glycoproteins: SARS-CoV (Urbani; AAP1344), murine hepatitis v
CoVOC43 (AAT84362), feline infectious peritonitis virus (FIPV; VGIH79), porcine t
CoVs 229E (AAK32191) and NL63 (AAS58177). The regions containing the fur
conserved S2 nonamer (gray) were manually adjusted to yield the alignment shown.
CoV and the group 1 viruses (.) are arbitrarily displayed. (B) The two basic residues
K672) are indicated by diamonds. The furin protease recognition sites engineered aIn this report, we examined the effect of proteolytic cleavage
on the ability of the SARS-CoV S glycoprotein to mediate cell–
cell fusion and viral infectivity. We show that the introduction of
a prototypic furin recognition motif at R667 allows for efficient
cleavage of the mutant glycoprotein and increased cell–cell
fusion activity. Nonetheless, the cleaved S glycoprotein was not
able to enhance the infectivity of pseudotyped virions. These
findings reinforce, in the converse, the observations reported in
the naturally cleaved group 2 CoVs (Bos et al., 1997; de Haan et
al., 2004; Hingley et al., 2002) and call attention to the distinct,
albeit unclear, requirements for virion entry in the CoVs.
Results
Sequence analysis of CoV S glycoproteins
The amino acid sequence of the SARS-CoV S glycoprotein
was compared with that of representative CoVs of group 1
(HuCoV-229E, HuCoV-NL63, TGEV and FIPV) and group 2
(HuCoV OC43, MHV and BCoV) using the MAXHOM
algorithm (Sander and Schneider, 1991). Alignment within
the S1 receptor-binding domain was minimal, and meaningful
similarity was observed only in the S2 fusion domain. These
similarities include the N- and C-terminal heptad-repeat regions
that together comprise the α-helical core of the fusion-active
trimer-of-hairpins structure and the intervening ‘loop’ region.
Extending towards the N-terminus, the alignment could readily
be followed through to a well-conserved nonamer (IPTNFSISI)
at SARS-CoV positions 696–704 (Fig. 1A). In the group 2
viruses that are proteolytically cleaved (e.g., MHVand BCoV),
the furin protease recognition site lies 33 amino acids upstream
of this nonamer (RRAHR and RRSRR, respectively). The
HuCoV OC43 contains a variant site (RRSRG) at which
cleavage may also occur (Kunkel and Herrler, 1996). Further
upstream of the furin-like recognition site in the group 2
glycoproteins, we identified a GxCx motif that could also beoV S glycoprotein. (A) The MAXHOM algorithm (Sander and Schneider, 1991)
was used for the initial alignment of the full-length amino acid sequences of the
irus (MHV; AAA87062), bovine CoV (BCoV; AAF25499), human respiratory
ransmissible gastroenteritis virus (TGEV; AAT00645) and the human respiratory
in cleavage site (in group 2 viruses; underlined) and the S1 GxCx motif and
A tyrosine (Y) present in all S1 domains is also underlined. Deletions in SARS-
in the junctional region of the wild-type SARS-CoV S glycoprotein (R667 and
t these sites are underlined in the HTR, HTVR and SLLR mutants.
Fig. 2. Serine mutation at R667, but not K672, reduces the ability of the S
glycoprotein to mediate cell–cell fusion. (A) Wild-type SARS-CoV S
glycoprotein and the R667S and K672S mutants were metabolically labeled
in COS-7 cells and isolated using the C-terminal S-peptide (Spep) affinity tag
(Kim and Raines, 1993). The mock lane represents cells transfected without
vTF7-3 infection. Proteins were resolved by SDS polyacrylamide gel
electrophoresis in NuPAGE 3–8% Tris–acetate gels (Invitrogen) either as the
isolated glycoproteins (above) or following deglycosylation using PNGase F
(below). The Endo-H-resistant (Sr) and Endo-H-sensitive (Ss) forms of the S
glycoprotein are indicated, as is the fully deglycosylated S polypeptide (S).
[14C]-methylated Rainbow molecular weight markers are indicated. The images
are printed dark to highlight the absence of proteolytic cleavage. (B) The ability
of the S glycoproteins to promote ACE2-dependent cell–cell fusion was
detected using the recombinant vaccinia virus-based β-galactosidase reporter
assay (Nussbaum et al., 1994; York et al., 2004). COS-7 cells expressing the
wild-type and mutant glycoproteins were co-cultured with COS-7 cells
transiently expressing the SARS-CoV cellular receptor ACE2 and infected
with the fusion reporter recombinant vaccinia virus vCB21R-lacZ (Nussbaum et
al., 1994; York et al., 2004). X-gal was used to detect β-galactosidase activity
arising from cell–cell fusion. The number of blue syncytia is shown from two
experiments, and error bars represent one standard deviation. Transfection
efficiencies were comparable in all cases.
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(Fig. 1A). We speculate that the conserved GxCx and nonamer
motifs delineate the junction between the S1 and S2 domains in
the SARS-CoV S glycoprotein.
We find considerable sequence variation and deletion
between the GxCx motif and the conserved S2 nonamer in
the uncleaved group 1 CoV S glycoproteins. In FIPV and
TGEV, the deletions remove all basic amino acids that might be
used in furin- or trypsin-mediated cleavage. By contrast, one or
more basic residues remain in the glycoproteins of SARS-CoV
and the human CoVs 229E and NL63. The alignment for these
human viruses in Fig. 1B highlights the single arginine at
position 667 of the SARS-CoV S glycoprotein, which may
signal a protease-sensitive site. Another basic residue in this
region of the SARS-CoV glycoprotein (lysine 672) may
likewise be relevant to protease recognition.
Mutation at R667, but not K672, affects
S-glycoprotein-mediated cell–cell fusion
Although biochemical evidence for proteolytic cleavage in
the wild-type SARS-CoV glycoprotein is largely negative
(Moore et al., 2004; Simmons et al., 2004; Song et al., 2004;
Xiao et al., 2003), we cannot exclude the possibility that trace
levels of cleavage by proteases that recognize single (trypsin-
like) or multiple (furin-like) basic residues may in fact be
responsible for S-glycoprotein-mediated membrane fusion. To
test this hypothesis, we mutated the two basic amino acids in the
presumptive S1–S2 junction region to serine. As shown in Fig.
2A (top), the wild-type, R667S and K672S glycoproteins were
comparably expressed to yield the intact S glycoprotein, which
migrated as two precursor bands: the mature, terminally
glycosylated form of 220 kDa molecular weight (Sr) and an
Endo H-sensitive (Ss) form of 200 kDa ((Song et al., 2004) and
K.E.F. and J.H.N, unpublished). These collapse upon deglyco-
sylation with PNGase F to yield the 140 kDa S polypeptide (Fig.
2A, bottom). The R667S and K672S mutations did not appear
to alter the expression or glycosylation of the glycoproteins, and
we too find no evidence of proteolytic cleavage to form S1 and
S2 subunits. Interestingly, however, the ability of the R667S
mutant to promote cell–cell fusion was consistently reduced to
60% of wild-type levels (Fig. 2B). Fusion by the K672S mutant
was largely unaffected. These results point to R667 as an
important amino acid in the S glycoprotein and perhaps as a site
susceptible to proteolytic cleavage.
Insertion of furin recognition sites in the SARS-CoV S
glycoprotein
To investigate whether proteolytic cleavage at the basic
amino acid residues, were it to occur, might facilitate cell–cell
fusion activity, we mutated the wild-type SARS-CoV glyco-
protein to construct a prototypic furin recognition site (RRSRR)
at either position. Based on our alignment, we engineered three
variants (Fig. 1B): one at position R667 to replace the resident
sequence with YHTRRSRR (referred to as HTR) and another at
the same position designed to accommodate the deletionindicated in the alignment, YHTVRRSRR (HTVR). The
sequence at K672 (RSTSQK) was shortened to RRSRR in
order to include the two naturally occurring basic residues (the
SLLR variant). These furin-site-containing glycoproteins were
expressed in COS-7 cells and isolated using the C-terminal
affinity tag (Fig. 3). Proteolytic cleavage to yield novel subunits
of 110 kDa and 90 kDa was apparent in the HTVR glycoprotein
and less so in HTR (top left). Little cleavage was seen in the
SLLR glycoprotein. The proteolytically cleaved products
appear to be derived from the mature, terminally glycosylated
Sr form of the S glycoprotein as the 220 kDa form in HTVR was
consistently reduced relative to the Ss form. This result is in
keeping with the subcellular localization of the furin protease in
the trans-Golgi network (Molloy et al., 1999; Rockwell et al.,
2002). Upon deglycosylation with PNGase F, the two novel
subunits in HTVR and HTRmigrated as 72 and 64 kDa peptides
(bottom, left), consistent with the anticipated molecular weights
of the predicted S1 and S2 polypeptides, respectively. The S2
polypeptide was typically accompanied by lower molecular
forms, which suggest additional N-terminal cleavage events. As
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2001), the S1 and S2 subunits derived from the furin-site-
containing glycoproteins remain associated upon cell lysis in
nonionic detergent.
The virus-neutralizing S-glycoprotein-specific monoclonal
antibody (MAb) F26G18 (Berry et al., 2004) recognizes a
predominantly linear epitope in the S1 subunit of the SARS-
CoV S glycoprotein (unpublished). This enabled us to
determine whether the S1 subunit was shed from the
proteolytically cleaved complex, as has been reported for the
naturally cleaved MHV S glycoprotein (Krueger et al., 2001).
Upon immunoprecipitation from the medium (Fig. 3; right), the
S1 subunit was readily isolated in cultures expressing HTVR
and HTR. A small amount of S1 was also shed from the SLLR
mutant. No S1 subunit was found in the culture medium from
cells expressing the wild-type SARS-CoV S glycoprotein,
consistent with the lack of proteolytic cleavage. Taken together,
these studies indicate that proteolytic cleavage of the SARS-
CoV S glycoprotein can be achieved by the introduction of a
furin recognition motif, especially at R667. The differences in
the degree of cleavage between the two R667 mutants, and in
SLLR, suggest specificity in the recognition of the engineered
furin sites.
HTVR is transported to the cell surface as the wild-type
glycoprotein
Based on our observation that the S1 subunit is shed from
cells expressing the furin-site-containing glycoproteins, we
investigated the expression and receptor-binding capability ofFig. 3. Proteolytic cleavage of the S glycoprotein at introduced furin sites. Wild-
type S glycoprotein and the furin-site-containing mutants HTVR, HTR and
SSLR were metabolically labeled in COS-7 cells. The S glycoprotein in cell
lysates was affinity isolated (cells; left panels), whereas the S1 subunit in the cell
culture supernatant (medium; right panels) was immunoprecipitated using MAb
F26G18 (Berry et al., 2004). Polypeptides obtained upon deglycosylation with
PNGase F are shown in bottom panels. Molecular weight markers and S
glycoforms are as described in Fig. 2A. Both S1 and S2 polypeptide molecular
weights are consistent with cleavage in the junctional region.the complex on the cell surface. COS-7 cells transiently
expressing the wild-type and HTVR glycoproteins were stained
to detect the S1 domain using MAb F26G18 (Berry et al.,
2004). Upon flow cytometric analysis (Fig. 4), the population of
positively staining cells was comparable in number and
fluorescence intensity in both the wild-type and HTVR mutant,
suggesting comparable transport and cell-surface expression of
the two glycoproteins. Studies using recombinant soluble ACE2
(Fig. 4) failed to demonstrate significant differences in the
capacity of the cell-surface glycoproteins to bind receptor.
Membrane fusion activity of the furin-site-containing mutant
glycoproteins
We then investigated the consequences of proteolytic
cleavage on the ability of the SARS-CoV S glycoprotein to
mediate membrane fusion. As shown in Fig. 5, COS-7 cells
expressing the HTVR glycoprotein were markedly enhanced in
their ability to fuse with cells expressing the ACE2 receptor. In
multiple experiments, this mutant generated 3- to 8-fold more
syncytia than did the wild-type S glycoprotein. The HTR
glycoprotein was also more fusogenic than the wild-type (1.8
fold), whereas the insertion in SLLR appeared to inhibit fusion.
Discounting potential detrimental effects of the amino acid
substitutions per se, the fusogenicity of the mutant glycopro-
teins generally correlated with the extent of proteolytic cleavage
(Fig. 3). Recombinant expression of ACE2 receptor was
required in all cases for fusion. The marked increase in
fusogenicity in concert with proteolytic cleavage suggests
strongly that proteolytic maturation of the CoV S glycoprotein
impacts the ability of the glycoprotein to mediate membrane
fusion.
Proteolytic cleavage of the mutant glycoproteins is mediated by
furin protease
We further investigated our assumption that proteolytic
cleavage in the furin-site-containing mutants is mediated by the
furin protease, and not by adventitious cellular enzymes that
may also cleave at the highly hydrophilic furin recognition site.
A Chinese hamster ovary (CHO) cell line deficient in furin
protease (FD11; (Gordon et al., 1995)) was obtained from S.
Leppla (NIH) and used to express the S glycoproteins. The
FD11 cell line was derived following chemical mutagenesis and
selection for resistance to anthrax toxin protective antigen (PA),
which is activated intracellularly by furin cleavage (Gordon et
al., 1995). As shown in Fig. 6, proteolytic processing of the
HTVR, HTR and SLLR glycoproteins was abrogated in the
furin-deficient FD11 cell line. The S1 and S2 subunits were
absent in FD11 cells, and S1 was not detected in the cell culture
medium. These findings provide evidence that proteolytic
cleavage in the furin-site-containing mutants is indeed mediated
by the furin protease.
Efforts to determine the relative fusogenicity of the cleaved
and uncleaved glycoproteins in the CHO and FD11 cells were
confounded, however, by differences in the levels of S
glycoprotein expression. Although cell–cell fusion by both
Fig. 4. Flow cytometric analysis of cell surface S glycoprotein. COS-7 cells transiently expressing the wild-type and HTVR mutant S glycoproteins were stained using
either (top) MAb F26G18 (Berry et al., 2004) and a secondary fluorescein isothiocyanate (FITC)-conjugated anti-mouse antibody or (bottom) a recombinant soluble
ACE2 receptor, biotinylated goat anti-ACE2 antibody and FITC-conjugated streptavidin. Cells were analyzed using a FACSCalibur flow cytometer (BD Biosciences),
and propidium-iodide-staining (dead) cells were excluded. Background staining of mock-transfected cells is shown in the left panel; non-expressing cells are also
evident in the transfected cell populations. Expressing cells were defined using a gate of ≥30 (<0.1% of the mock-transfected population).
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reduced in furin-deficient FD11 cells (Fig. 7B), the relative
transfection efficiencies in the two cell lines also differed
markedly (4% vs. 20% in the parental CHO cells). The basis for
this difference is unclear and was not mitigated in a furin-
expressing cell line derived from FD11 (Gordon et al., 1995).
Direct comparison of fusion activity in the two cell lines was
therefore difficult.
To circumvent this problem, we co-expressed the S
glycoprotein with furin cDNA in FD11 cells. As anticipated,
recombinant furin expression was required for proteolytic
cleavage of the HTVR glycoprotein in FD11 cells (Fig. 7A).
Despite the reduced levels of S glycoprotein expression in the
FD11 cells, S1 and S2 subunits were generated and S1
glycoprotein was shed into the culture medium with good
efficiency. Cell–cell fusion by the HTVR glycoprotein was also
enhanced by co-expression of furin in FD11 cells (Fig. 7B).
Interestingly, the wild-type S glycoprotein was also cleaved in
CHO cells co-expressing the furin cDNA to yield S1 and S2
subunits that co-migrated with those in the HTVR glycoprotein
(Fig. 7A). This may represent exuberant cleavage at the
suboptimal SLLR667 site in the wild-type glycoprotein.
Concomitant with this cleavage event, cell–cell fusion by the
wild-type S glycoprotein was enhanced by co-expression of
furin (Fig. 7B). In addition to the nominal S1 subunit, these cells
also shed a larger glycoprotein (indicated by the asterisk in Fig.
7A) whose molecular weight is consistent with cleavage at apreviously suggested furin recognition motif at position 758–
761 (RNTR (Xiao et al., 2003)), a site we place by sequence
alignment in the S2 subunit (Fig. 1A).
The dramatic effects observed upon co-expression of furin in
an experimental setting raise the possibility of cryptic cleavage
events in the wild-type S glycoprotein under natural conditions.
The ability of the co-expressed furin to cleave the wild-type
glycoprotein to produce S1 and S2 subunits that co-migrate with
those generated in the HTVR mutant lends credence to the
suggestion that the S1–S2 junctional region defined by
sequence alignment (Fig. 1) may contain vestigial or ineffi-
ciently utilized furin recognition sites.
R667 is important for furin-mediated cleavage in the wild-type
S glycoprotein
To specifically determine which of the basic residues within
the junctional region is utilized for cleavage of the wild-type S
glycoprotein, we re-examined the expression of the R667S and
K672S mutant glycoproteins in CHO cells co-transfected to
over-express the furin cDNA. S1 and S2 subunits were
generated in cell lysates of both the wild-type and K672S
glycoproteins, but not in the R667S mutant. Consistent with
this finding, only cells expressing the wild-type and K672S
glycoproteins were able to shed S1 glycoprotein to the cell
culture medium (Fig. 8A). These findings suggest that the
furin-mediated cleavage event at R667 is disrupted by the
Fig. 6. Proteolytic processing in furin-deficient FD11 and wild-type CHO cells.
Wild-type S glycoprotein and the furin-site-containing mutants HTVR, HTR
and SSLR were metabolically labeled in furin-deficient cells and parental CHO
cells (Gordon et al., 1995). The S glycoprotein in cell lysates was affinity
isolated (top panels), and the S1 subunit in the cell culture medium (bottom
panels) was immunoprecipitated using MAb F26G18 (Berry et al., 2004).
Fig. 5. Cell–cell fusion is enhanced by proteolytic cleavage. Wild-type S
glycoprotein and the furin-site-containing mutants HTVR, HTR and SSLR were
expressed in COS-7 cells, and fusogenicity was determined as described in Fig.
2B (Nussbaum et al., 1994; York et al., 2004). The number of blue syncytia
relative to that in the wild-type S glycoprotein control is shown from four
independent experiments, and error bars represent one standard deviation.
Transfection efficiencies within each experiment were comparable.
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generation of the S1 subunit in the wild-type and HTVR
glycoproteins. By contrast, the larger S1-like fragment thought
to represent cleavage at the RNTR site at position 758–761
(indicated by the asterisk in Fig. 8A) was produced and shed
by both the R667S and K672S mutants and by the wild-type
glycoprotein.
We had shown that the membrane fusion activity of the
R667S glycoprotein was reduced in COS-7 cells relative to the
wild-type glycoprotein (Fig. 2B), and a similar result was
obtained in CHO cells (Fig. 8B). Co-expression of furin cDNA
in the CHO cells resulted in a 5-fold increase in fusion activity
by the wild-type and the K672S glycoproteins (Fig. 8B). The
increase was considerably blunted in the R667S mutant,
consistent with the reduction in furin-mediated cleavage at the
mutated SLLS667 site. Thus, maximal cell–cell fusion activity
correlates with the presence of the S1 subunit generated by
cleavage at R667. The larger S1-like product, generated in all
the glycoproteins and thought to reflect cleavage at position
761, is likely not a key contributor to fusion competence.
Enhanced cell–cell fusion activity does not translate to
increased virion infectivity
Studies of the normally cleaved S glycoprotein of group 2
MHVs have highlighted a clear and puzzling distinction
between the roles of proteolytic cleavage in cell–cell fusion
and in virion infectivity and pathogenicity (Bos et al., 1997; de
Haan et al., 2004; Hingley et al., 2002). To determine whether
proteolytic cleavage of the normally uncleaved SARS-CoV S
glycoprotein affects virion infectivity, we generated pseudo-
typed retroviral virions bearing the wild-type and HTVR SARS-
CoV glycoproteins (Moore et al., 2004; Simmons et al., 2004;
Yang et al., 2004; Yuan et al., 2004). For these studies, we
utilized the HIV-1 provirus-based vector pNL4-3.Luc.R−E−,
which has been engineered to disrupt HIV envelope glycopro-
tein expression and to encode a luciferase reporter protein
(Connor et al., 1995). A codon-optimized S glycoprotein gene
(Moore et al., 2004) was provided by M. Farzan (HarvardMedical School, Boston) to obviate the need for vTF7-3 in these
studies. The codon-optimized gene was further modified to
delete the C-terminal 19 amino acids (co-S Δ19) that interfere
with pseudotyping efficiency (Fukushi et al., 2005; Giroglou et
al., 2004; Moore et al., 2004). Purified pseudotyped virions
bearing the wild-type co-S Δ19 glycoprotein or the HTVR-
derivative were initially examined by immunoprecipitation to
characterize pseudotype formation (Fig. 9A). Comparable
levels of HIV Gag proteins p24 and p17 were found in
pseudotyped particles bearing either co-S Δ19 or co-HTVR
Δ19 glycoproteins. Importantly, comparable amounts of the
two S glycoproteins were incorporated into the retroviral
particles. Pseudotyped virions containing the HTVR glycopro-
tein were highly enriched in the cleaved subunits (S1 and S2)
relative to the expressing cells (e.g., Fig. 3), although the
uncleaved form was also present. This enrichment is likely due
to the exclusion of immature intracellular forms of the
glycoprotein from the pseudotyped virion sample. As antici-
pated, no cleaved S glycoprotein products were observed in
virions bearing the wild-type co-S Δ19 glycoprotein. Thus, the
respective S glycoproteins are comparably and faithfully
incorporated into pseudotyped virions.
To determine the infectivity of the respective pseudotyped
virions, cell culture supernatants were incubated with human
293T cells expressing the ACE2 receptor, and viral entry was
assessed 2 days later by expression of the luciferase gene
reporter. Despite the dramatic differences observed in assays of
cell–cell fusion, pseudotyped virions bearing the co-S Δ19 or
co-HTVR Δ19 glycoprotein were equally infectious (Fig. 9B).
Expression of the ACE2 receptor remained essential for entry.
Thus, the enhanced facility of the furin-cleaved HTVR
glycoprotein to mediate membrane fusion is apparently not
reflected in the overall process of virion entry. The disconnect
between the membrane fusion activity of the S glycoprotein and
its ability to mediate viral entry, demonstrated here in the
Fig. 7. Co-expression of furin cDNA enhances proteolytic cleavage and cell–cell fusion. (A) Wild-type or HTVR S glycoprotein plasmid was co-transfected with a
furin-expressing plasmid (+furin cDNA), or a pcDNA3.1− control (−furin cDNA), into furin-deficient FD11 or wild-type CHO cells (Gordon et al., 1995). The S
glycoproteins were expressed and metabolically labeled as described in Fig. 3. Isolated glycoproteins from cell lysates (top panel) were also examined following
deglycosylation with PNGase F (middle panel); shed S1 subunit was immunoprecipitated from the cell culture medium and examined following deglycosylation
(bottom panel). Molecular weight markers and forms of the S glycoprotein are as described in Fig. 3. A 69 kDa molecular weight form of S1 was also detected in the
culture medium upon PNGase F-treatment (indicated by *), as was a 140 kDa polypeptide which is consistent with blebbing of the intact S glycoprotein. (B) Cell–cell
fusion was assessed using the indicated S-glycoprotein-expressing cells and COS-7 target cells expressing exogenous ACE2 receptor. The number of blue syncytia is
shown from two experiments, and error bars represent one standard deviation. Small error bars are not shown.
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in the normally cleaved glycoprotein of MHV (Bos et al., 1997;
de Haan et al., 2004; Hingley et al., 2002), highlights
unresolved complexities in the pathway used by CoVs to infect
target cells.Fig. 8. Co-expression of furin cDNA results in cleavage and enhanced fusogenicity of
plasmid (R667S or K672S) was co-transfected into wild-type CHO cells with a fur
Isolated glycoproteins from cell lysates (cells; top panel) and immunoprecipitated S1
F. Molecular weight markers and forms of the S polypeptide, including the larger S1
medium (bottom panel) is shown for internal size reference. (B) Cell–cell fusion was
expressing exogenous ACE2 receptor. The number of blue syncytia is shown from tw
are not shown.Discussion
The paradigm developed from the study of other Class I
viral fusion proteins – that proteolytic maturation of a
precursor glycoprotein is absolutely required to activate thethe wild-type and K672S glycoproteins. (A) Wild-type or mutant S glycoprotein
in-expressing plasmid (+furin cDNA) or a pcDNA3.1− control (−furin cDNA).
subunit from culture medium (bottom panel) were deglycosylation with PNGase
fragment (*), are as described in Fig. 7. The intact S polypeptide present in the
assessed using the S-glycoprotein-expressing CHO cells and COS-7 target cells
o experiments, and error bars represent one standard deviation. Smaller error bars
Fig. 9. Pseudotyped virions bearing HTVR S glycoprotein are not enhanced in their infectivity. (A) Metabolically labeled pseudotyped virions bearing the co-SΔ19 or
co-HTVR Δ19 glycoprotein were pelleted through 20% sucrose and solubilized in 1% Triton X-100 lysis buffer prior to immunoprecipitation. HIV proteins were
isolated using anti-HIV immunoglobulin from infected individuals (HIVIG; Prince et al., 1991), and SARS-CoV S glycoproteins were immunoprecipitated usingMAb
F26G18 (Berry et al., 2004). Particles lacking any envelope glycoprotein (null) served as controls. S-glycoprotein-containing samples were heated to 100 °C prior to
SDS-PAGE electrophoresis to disrupt S2 oligomers. Molecular weight markers, HIV proteins (Gag p24 and p17) and forms of the S glycoprotein are indicated. (B)
Pseudotyped virions bearing the co-S Δ19 or co-HTVR Δ19 glycoprotein, or the VSV G glycoprotein control, were used to infect 293T cells transiently expressing
ACE2 (+) or native 293T cells (−). Fresh pseudotyped virion stocks were applied neat to 293T cell microcultures, and infection was determined 2 days later by
chemiluminescence of the luciferase reporter (reported in relative light units (RLUs)). No infection by S-glycoprotein-containing virions was detected (ϕ) in the
absence of ACE2 expression. Error bars represent one standard deviation.
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not neatly applied to the CoV S glycoprotein. Some naturally
occurring CoV S glycoproteins undergo proteolytic cleavage
(those of the group 2 and 3 CoVs) and others do not (those of
the group 1 viruses). Judging that it is unlikely that a
proteolytically intact S glycoprotein is capable of mediating
membrane fusion, one is left to consider the alternative that the
fusion activity of the group 1 viruses, and the newly emerged
SARS-CoV, may derive from proteolytic cleavage that has
heretofore gone undetected. In this report, we have examined
the role of furin cleavage on the fusogenicity of the normally
uncleaved SARS-CoV S glycoprotein. We found that intro-
duction of a synthetic furin recognition sequence at R667 in
the putative S1–S2 junctional region enabled efficient cleavage
of the S glycoprotein to generate discrete S1 and S2 subunits
and markedly increased the ability of the spike complex to
mediate cell–cell fusion. In the wild-type S glycoprotein, over-
expression of furin cDNA made manifest a cleavage event that
has not been otherwise observed (see also Bergeron et al.,
2005), most likely at the naturally occurring sequence
SLLR667. This exuberant cleavage likewise resulted in an
increase in fusogenicity. Direct physical confirmation of
cleavage at R667 is however lacking. Although a synthetic
peptide bearing the SLLR site was insensitive to furin cleavage
in vitro (Bergeron et al., 2005), it is possible that this sequence
may be recognized under some natural conditions. For
instance, cleavage might take place on the extracellular virion,
perhaps in specialized tissue environments (Klenk and Garten,
1994) or upon endocytosis (Nash and Buchmeier, 1997;
Simmons et al., 2004; Yang et al., 2004).In our studies, we show a consistent correlation between
furin cleavage at SLLR667 and an increased ability of the
glycoprotein to mediate cell–cell fusion. By contrast, furin-
mediated cleavage of the S glycoprotein at a more C-terminal
recognition motif, RNTR761, does not appear to affect
fusogenicity. Although cleavage at these sites has previously
been reported (Bergeron et al., 2005), our studies demonstrate
the importance of the SLLR667 cleavage in fusion competence
of the S glycoprotein. This finding is in agreement with the
evolutionary homology in this S1–S2 junctional region among
CoV species (Fig. 1).
Based on the widespread conservation of furin recognition
sites in the group 2 and 3 CoVs, we have focused on this
protease. Interestingly, inhibition of furin activity by a peptidic
furin inhibitor has recently been reported to prevent the
cytopathic effect of SARS-CoV infection in cell culture
(Bergeron et al., 2005). Nonetheless, other proteolytic enzymes
have also been implicated in CoV entry (Matsuyama et al.,
2005; Simmons et al., 2004; Storz et al., 1981; Sturman et al.,
1985). The recent finding that SARS-CoVentry can be blocked
by a specific inhibitor of cathepsin L (Huang et al., 2006;
Simmons et al., 2005) highlights the possible role of endosomal
proteases. The multiple opportunities for proteolytic activation
of the S glycoprotein in natural infection remain to be
examined.
The specific facilitation of cell–cell fusion activity by furin
cleavage of the SARS-CoV S glycoprotein reported here
extends previous findings from studies of the naturally cleaved
group 2 CoVs, in which reductions in S glycoprotein cleavage
have been associated with deficiencies in cell–cell fusion
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1985; Taguchi, 1993; Yamada et al., 1998). Despite a
reasonable correlation between proteolytic cleavage and
membrane fusion activity in both the naturally cleaved and
uncleaved S glycoproteins, the presence or absence of furin
cleavage appears to have surprisingly little impact on the
infectivity of the virion particle. MHV virions that contain
significant mutations in the furin-recognition site are not
proteolytically cleaved yet remain infectious and pathogenic
(Bos et al., 1997; de Haan et al., 2004; Hingley et al., 2002).
Here, we demonstrate the converse—that pseudotyped virions
bearing the cleaved HTVR glycoprotein are no more capable of
mediating virion entry than those bearing the uncleaved wild-
type S glycoprotein.
The discordant effects of proteolytic cleavage highlight the
potential for differences in the requirements and pathways for S-
glycoprotein-mediated cell–cell fusion and viral entry. This
dichotomy is further reflected in the ability of exogenous trypsin
to enhance SARS-CoV S-glycoprotein-mediated cell–cell
fusion, but not infectivity by pseudotyped virion (Simmons et
al., 2004). Reciprocally, cell–cell fusion by the MHV S
glycoprotein is prevented by a peptidic furin inhibitor, whereas
MHV infection is not (de Haan et al., 2004).
The recent finding that SARS-CoV entry is blocked by a
specific inhibitor of the endosomal protease cathepsin L
provides one plausible resolution to this conundrum (Huang
et al., 2006; Simmons et al., 2005): the cleavage critical for viral
entry may take place unobserved upon endocytosis or during
vesicular trafficking. Other cleavage events mediated by furin,
while evolutionarily conserved and no doubt important, may
serve supportive or even distinct functions. A similar paradigm
has been proposed for entry by the Ebola filovirus (Chandran et
al., 2005). As in MHV, furin cleavage of the Ebola virus
envelope glycoprotein precursor occurs in nature yet appears
unnecessary for viral entry (Neumann et al., 2002; Wool-Lewis
and Bates, 1999).
Although further investigation of the role of endosomal
proteases in viral entry will no doubt reveal additional detail
to this novel mechanism for envelope glycoprotein activation,
the function of the highly conserved furin cleavage site in the
CoV life cycle remains unclear. In this regard, it is
worthwhile to note another trait of the CoV S glycoproteins
that is phylogenetically linked to the presence or absence of
the furin cleavage site. In the ectodomain of S glycoproteins
that remain uncleaved (group 1 CoVs), the N- and C-terminal
heptad-repeat regions are extended by two additional in-
register units (14 amino acids) relative to those of S
glycoproteins that normally undergo furin cleavage (groups
2 and 3 CoVs). These heptad-repeat regions in Class I viral
fusion proteins form the six α-helical core of the trimer-of-
hairpins structure upon envelope glycoprotein activation and,
in doing so, contribute energetically toward the initiation of
membrane fusion ((Eckert and Kim, 2001; Hughson, 1997;
Skehel and Wiley, 2000; Weissenhorn et al., 1999) and
references therein). By this model, the extended heptad
repeats in the group 1 viruses may facilitate formation of the
six-helix bundle and membrane fusion, perhaps in compen-sation for the lack of furin cleavage. Biophysical and
structural evidence for this suggestion is however lacking.
It is of interest, then, that the S glycoproteins of the SARS-
CoVand its related CoVs (Guan et al., 2003; Lau et al., 2005; Li
et al., 2005) represent an exception to this rule in the other
CoVs. Despite the lack of furin cleavage, these glycoproteins
contain only the shorter heptad-repeat regions. The conse-
quences of this exception for viral replication, pathogenesis and
CoVecology are unknown. Further studies of CoVentry and the
role of proteolytic cleavage events in this process are likely to
impact our understanding of CoV pathogenesis and our ability
to respond to newly emerging CoVs.
Materials and methods
Molecular reagents and monoclonal antibodies
The S glycoprotein gene of the Urbani isolate of SARS-CoV
(Ksiazek et al., 2003) was obtained from P. Rota (Centers for
Disease Control and Prevention, Atlanta) and adapted for
expression in pcDNA3.1− (Invitrogen). We further modified
this plasmid to introduce an S-peptide (Spep) affinity tag (Kim
and Raines, 1993) at the cytoplasmic C-terminus of the S
glycoprotein to facilitate manipulations. The Spep addition is
innocuous with regard to S-glycoprotein-mediated membrane
fusion (Follis et al., 2005), in keeping with reports of other C-
terminal tags (Bisht et al., 2004; Bosch et al., 2004; Moore et al.,
2004). Mutations were introduced by using QuikChange
mutagenesis (Stratagene) and confirmed by DNA sequencing.
A plasmid encoding the cell surface receptor of the SARS-CoV,
angiotensin-converting enzyme 2 (ACE2) was provided by M.
Farzan (Harvard Medical School, Boston) (Li et al., 2003).
Mouse monoclonal antibodies (MAbs) directed to the S
glycoprotein were provided by J. Berry (National Microbiology
Laboratory, Public Health Agency of Canada, Winnipeg) (Berry
et al., 2004; Gubbins et al., 2005). The human furin precursor
cDNA (Bresnahan et al., 1990) was from G. Thomas (Oregon
Health Sciences University, Portland) and was transferred to
pcDNA3.1− for expression. Wild-type Chinese hamster ovary
(CHO) cells and the furin-deficient derivative FD11 (Gordon et
al., 1995) were provided by S. Leppla (National Institutes of
Health, Bethesda).
Expression of the S glycoprotein
The full-length S glycoprotein was transiently expressed
using the pcDNA3.1− T7 promoter and the recombinant
vaccinia virus vTF7-3 encoding T7 polymerase (Follis et al.,
2005; Fuerst et al., 1986). vTF7-3 was obtained from T. Fuerst
and B. Moss (National Institutes of Health) through the NIH
AIDS Research and Reference Reagent Program. COS-7 cells
were infected with the recombinant vaccinia virus at a
multiplicity of eight in Dulbecco's Minimal Essential Medium
(DMEM) containing 2% fetal bovine serum (FBS). Cytosine
arabinoside (araC) was added to the medium at 10 μM to limit
vaccinia virus expression (Hruby et al., 1980). CHO cells were
infected at a multiplicity of eight in F12 medium containing 2%
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with the S glycoprotein expression plasmid using FuGene-6
reagent (Roche Biochemicals). Metabolic labeling using 80
μCi/ml of [35S]-ProMix (Amersham Pharmacia Biotech) was
initiated 6 h post-transfection in methionine- and cysteine-free
DMEM containing 10% dialyzed FBS and 10 μM araC and was
continued for 12–16 h. Cell culture supernatants were collected,
cleared and filtered (0.2 μm) and were made to 1% Triton X-100
and 1 μg/ml each of protease inhibitors (aprotinin, leupeptin and
pepstatin) prior to immunoprecipitation using the S1 domain-
directed MAb F26G18 (Berry et al., 2004) and Protein A–
Sepharose (Sigma). Cells were washed in physiological
buffered saline (PBS) and lysed using cold Tris–saline buffer
(50 mM Tris–HCl and 150 mM NaCl at pH 7.5) containing 1%
Triton X-100 nonionic detergent and protease inhibitors. A
soluble fraction was prepared by centrifugation at 15,000 × g for
15 min at 4 °C. The S glycoproteins in cell lysates were isolated
using the Spep affinity tag and S-protein agarose (Novagen).
Comparable results were obtained by immunoprecipitation
from cell lysates (not shown). In some studies, the glycoproteins
were deglycosylated using peptide N-glycosidase (PNGase F;
New England Biolabs). The isolated glycoproteins and
deglycosylated polypeptides were resolved using NuPAGE 3–
8% Tris–acetate gels (Invitrogen) and the recommended sample
buffer containing lithium dodecyl sulfate and reducing agent.
Molecular size markers are [14C]-methylated Rainbow proteins
(Amersham Pharmacia Biotech). Radiolabeled proteins were
imaged using a Fuji FLA-3000G imager and analyzed using
ImageGauge software (Fuji).
Flow cytometry
COS-7 cells transiently expressing the SARS-CoV S
glycoprotein were labeled using either the S1-directed MAb
F26G18 (Berry et al., 2004) and a secondary fluorescein-
isothiocyanate (FITC)-conjugated goat anti-mouse antibody
(Jackson ImmunoResearch) or with recombinant soluble ACE2
receptor (R&D Systems; 0.5 μg in 100 μl), biotinylated goat
anti-ACE2 antibody (R&D Systems) and FITC-conjugated
streptavidin (BD Biosciences). Cells were subsequently stained
using propidium iodide (1 μg/ml) and then fixed in 2%
formaldehyde. Populations were analyzed using a FACSCalibur
flow cytometer and CellQuest software (BD Biosciences).
S-glycoprotein-mediated cell–cell fusion
The β-galactosidase fusion reporter assay (Nussbaum et al.,
1994) was used to assess the ability of the S glycoproteins to
mediate receptor-dependent cell–cell fusion (Follis et al., 2005).
The recombinant vaccinia virus vCB21R-lacZ expressing β-
galactosidase under the control of the T7 promoter (Alkhatib et
al., 1996) was obtained from C. Broder, P. Kennedy and E.
Berger (NIH) through the NIH AIDS Research and Reference
Reagent Program. In these studies, cells infected with vTF7-3
and expressing the S glycoprotein were co-cultured with target
COS-7 cells transfected to express the SARS-CoV cellular
receptor ACE2 (Li et al., 2003) and infected with vCB21R-lacZ.Upon fusion of the effector and target cells, β-galactosidase
expression was induced. To generate the target cell population,
COS-7 cells that had been transfected 1 day previously with the
ACE2 expression plasmid (Li et al., 2003) were incubated with
vCB21R-lacZ at a multiplicity of 10 and the infection was
allowed to proceed overnight in the presence of 100 μg/ml of
the vaccinia virus assembly inhibitor rifampicin. The following
day, S-glycoprotein-expressing cells and ACE2-expressing
target cells were co-cultured for 10 h in medium containing
both araC and rifampicin (Hruby et al., 1980; York et al., 2004).
Cultures were then fixed for 5 min at 4 °C in cold PBS
containing 2% formaldehyde and 0.2% glutaraldehyde, and β-
galactosidase activity was detected using the chromogenic X-
gal substrate (Nussbaum et al., 1994). The numbers of blue
syncytia per 24-well microculture dish were determined
microscopically.
Pseudotyped virions
Lentiviral virions bearing the SARS-CoV S glycoprotein
were generated using the HIV-1 proviral vector pNL4-3.Luc.
R−E− (Connor et al., 1995) obtained through the NIH AIDS
Research and Reference Reagent program from N. Landau
(Salk Institute, La Jolla, CA). To eliminate the requirement for
recombinant vaccinia virus vTF7-3 in these studies, a codon-
optimized S glycoprotein gene (Urbani strain; co-S-C9; Moore
et al., 2004) was obtained from M. Farzan (Harvard Medical
School, Boston). The S glycoprotein reading frame was
subsequently modified to remove the C-terminal tag, to generate
the HTVR mutation and to delete the C-terminal 19 amino
acids. This latter Δ19 truncation increased the efficiency of
pseudotyping (Fukushi et al., 2005; Giroglou et al., 2004;
Moore et al., 2004). A plasmid expressing the vesicular
stomatitis virus (VSV) G glycoprotein was provided by J.
Rose (Yale University) and served as a control in our studies.
Pseudotyped virions were generated by co-transfection of the
pNL4-3.Luc.R−E− and pcDNA3.1-based envelope glycopro-
tein-expressing plasmids at a 4:1 ratio in COS-7 cells.
Supernatants were harvested after 2 days and filtered (0.45
μm produce pseudotyped virion stocks. In these experiments,
transfection efficiencies in the cultures were gauged by
expression of the pNL4-3.Luc.R−E−-encoded luciferase gene.
Chemiluminescence was assayed using Luc-Screen System
reagents (Applied Biosystems) and a Tropix TR717 microplate
luminometer. Luciferase expression was comparable in trans-
fected cultures expressing either the wild-type or HTVR co-S
glycoprotein. Pseudotyped virion stocks were used fresh to
infect human 293T cells that had previously been transfected to
transiently express human ACE2. Infection was determined 2
days later by expression of the luciferase reporter.
Metabolically labeled pseudotyped virions were examined to
characterize the relative efficiency of S glycoprotein incorpo-
ration. Transfected cultures were labeled for 24 h prior to
harvest using 80 μCi/ml of [35S]-ProMix (Amersham Pharma-
cia Biotech), and supernatant virions were purified by
ultracentrifugation through 20% sucrose. Pelleted particles
were lysed and immunoprecipitated using MAb F26G18 as
368 K.E. Follis et al. / Virology 350 (2006) 358–369described above. HIV proteins were separately precipitated
using anti-HIV immunoglobulin from infected individuals
(HIVIG; Prince et al., 1991).
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